Literature DB >> 32420256

Therapeutic efficacy of two surgical methods on the secondary hyperparathyroidism.

Chao Gu1, Zhenyu Ye2, Yanan Wang3, Qin Wang1, Jie Qi1, Jianhua Chen1, Shan Chen4, Zekuan Xu5.   

Abstract

BACKGROUND: This study aimed to investigate the clinical efficacy of two surgical methods on hyperparathyroidism secondary to uremia and summarize the advantages and disadvantages of both methods.
METHODS: Uremic patients who received parathyroidectomy (PTX) in the last 3 years were divided into two groups according to the surgical methods used [subtotal parathyroidectomy (SPTX) group and total parathyroidectomy + autologous implantation (TPTX + AT) group]. TPTX was performed if less than 4 glands were found during surgery. The changes of various indexes after operation, and calculate the success rate and recurrence rate of patients were observed. The serum biochemical parameters were routinely monitored, the success rate, postoperative complications and recurrence were recorded. The patients were followed up.
RESULTS: There were 20 patients in the SPTX group and 12 in the TPTX + AT group. The success rate of surgery was 85% and 91.7% in the SPTX group and TPTX + AT group, respectively, among 32 patients included for final analysis. The mean PTH and postoperative ALP in the TPTX + AT group were slightly lower than in the SPTX group, except for the PTH levels at 6 months after surgery (P<0.05). The incidence of postoperative hypocalcemia was 100% in both groups. The incidence of wound infection in the two groups was 0% and 16.7% in the SPTX group and TPTX + AT group, respectively. The mean calcium supplementation in the TPTX + AT group was significantly more than in the SPTX group within 1 year after surgery. The mean postoperative bone mineral density in the SPTX group was significantly higher than in the TPTX + AT group. The time to postoperative remission of bone pain and muscle weakness was markedly shorter in the SPTX group than in the TPTX + AT group. The post-operative quality of life (QOL) in the SPTX group was significantly better than in the TPTX + AT group.
CONCLUSIONS: These findings suggest that SPTX achieves a better short-term efficacy, but TPTX + AT has a better long-term efficacy. Therefore, the selection of surgical method for PTX may be based on the age, estimated survival time and possibility of kidney transplantation. 2020 Gland Surgery. All rights reserved.

Entities:  

Keywords:  Parathyroidectomy (PTX); secondary hyperparathyroidism (SHPT); surgical methods; uremia

Year:  2020        PMID: 32420256      PMCID: PMC7225472          DOI: 10.21037/gs.2020.03.08

Source DB:  PubMed          Journal:  Gland Surg        ISSN: 2227-684X


  18 in total

1.  Parathyroidectomy and survival among Japanese hemodialysis patients with secondary hyperparathyroidism.

Authors:  Hirotaka Komaba; Masatomo Taniguchi; Atsushi Wada; Kunitoshi Iseki; Yoshiharu Tsubakihara; Masafumi Fukagawa
Journal:  Kidney Int       Date:  2015-03-18       Impact factor: 10.612

Review 2.  [Management of secondary hyperparathyroidism-current impact of parathyroidectomy].

Authors:  Emanuel Zitt; Karl Lhotta
Journal:  Wien Med Wochenschr       Date:  2016-02-25

3.  The bone histology spectrum in experimental renal failure: adverse effects of phosphate and parathyroid hormone disturbances.

Authors:  Daniella G Batista; Kátia R Neves; Fabiana G Graciolli; Luciene M dos Reis; Rafael G Graciolli; Wagner V Dominguez; Carolina L Neves; Andrea O Magalhães; Melani R Custódio; Rosa M Moysés; Vanda Jorgetti
Journal:  Calcif Tissue Int       Date:  2010-04-29       Impact factor: 4.333

4.  [Surgical treatment of secondary hyperparathyroidism in patients with chronic renal failure].

Authors:  Mouna Hamouda; Nasr Ben Dhia; Sabra Aloui; Imene Gorsane; Habib Skhiri; Ameur Frih; Jamel Koobaa; Nabil Driss; Kamel Bouzouita; Mezri Elmay
Journal:  Nephrol Ther       Date:  2010-11-26       Impact factor: 0.722

5.  Parathyroidectomy in secondary hyperparathyroidism: Is there an optimal operative management?

Authors:  Melanie L Richards; Jennifer Wormuth; Juliane Bingener; Kenneth Sirinek
Journal:  Surgery       Date:  2006-02       Impact factor: 3.982

6.  Subtotal parathyroidectomy versus total parathyroidectomy with autotransplant in secondary hyperparathyroidism — a single-centre prospective cohort of 43 patients.

Authors:  Radu Mircea Neagoe; Mircea Mureșan; Septimiu Voidăzan; Ionela Pașcanu; Cristina Pop Radu; Daniela Tatiana Sala
Journal:  Endokrynol Pol       Date:  2016       Impact factor: 1.582

7.  Outcomes of Total Parathyroidectomy with Autotransplantation versus Subtotal Parathyroidectomy with Routine Addition of Thymectomy to both Groups: Single Center Experience of Secondary Hyperparathyroidism.

Authors:  Gürhan Sakman; Cem Kaan Parsak; Mustafa Balal; Gülşah Seydaoglu; Ismail Cem Eray; Gökhan Sarıtaş; Orhan Demircan
Journal:  Balkan Med J       Date:  2014-03-01       Impact factor: 2.021

Review 8.  Surgical and medical treatment of secondary hyperparathyroidism in patients on continuous dialysis.

Authors:  Yoshihiro Tominaga; Susumu Matsuoka; Nobuaki Uno
Journal:  World J Surg       Date:  2009-11       Impact factor: 3.352

9.  Subtotal parathyroidectomy for secondary renal hyperparathyroidism: a 20-year surgical outcome study.

Authors:  Aleksander Konturek; Marcin Barczyński; Małgorzata Stopa; Wojciech Nowak
Journal:  Langenbecks Arch Surg       Date:  2016-05-27       Impact factor: 3.445

Review 10.  Total parathyroidectomy versus total parathyroidectomy with autotransplantation for secondary hyperparathyroidism: systematic review and meta-analysis.

Authors:  Changjia Li; Liang Lv; Hongqiao Wang; Xufu Wang; Bangxu Yu; Yan Xu; Xiaobin Zhou; Yanbing Zhou
Journal:  Ren Fail       Date:  2017-11       Impact factor: 2.606

View more
  1 in total

1.  Association Between Treatment of Secondary Hyperparathyroidism and Posttransplant Outcomes.

Authors:  Aarti Mathur; Whitney Sutton; JiYoon B Ahn; Jason D Prescott; Martha A Zeiger; Dorry L Segev; Mara McAdams-DeMarco
Journal:  Transplantation       Date:  2021-12-01       Impact factor: 5.385

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.